Presentation on theme: "Detection and Treatment of Sexually Transmitted Infections"— Presentation transcript:
1Detection and Treatment of Sexually Transmitted Infections 27 March 2014Maj Jeremy King, M.D.
2ObjectivesUnderstand the causes, signs, and symptoms of sexually transmitted infections (STIs) that cause:Genital ulcersVaginitisCervicitisPelvic inflammatory diseaseUnderstand the rational for screening and the current recommended screening strategiesUnderstand recommended screening in special conditions such as pregnancy and sexual assault
3STIs in the US 20 million new infections per year. 110 million current infections.$16 billion in direct medical costs per year.Complications of untreated STIs: - upper genital tract infections - infertility, cervical cancer - enhanced transmission of HIVSatterwhite CL, et al. Sexually transmitted infections among U.S. women and men: Prevalence and incidence estimates, Sex Transm Dis 2013
4ScreeningScreening tests detect early disease or risk factors for disease in large numbers of apparently healthy individuals Diagnostic tests confirm the presence (or absence) of disease in symptomatic or screen positive individuals
5When should we screen? Tests are available Risk factors are present relatively inexpensive, reliable, prevent morbidityage, current sexual practices, past infectionseg: Chlamydia
6Chlamydia Reported Chlamydia Cases in Texas, 1992-2012 Almost 125,000 cases reported in 201276% FemaleDisproportionately BlackReported Chlamydia Cases in Texas,2012 Sexually Transmitted Diseases Surveillance
7Chlamydia Reported Chlamydia Cases in Texas, 1992-2012 Chlamydia in TX:Almost 125,000 cases reported in 201276% FemaleDisproportionately BlackReported Chlamydia Cases in Texas,2012 Texas STD and HIV Epidemiologic ProfileFebruary 2014
8Chlamydia 85% of cases are asymptomatic Potential complications: PIDChronic pelvic paintubal infertilityEctopic pregnancyScreening recommendations:All sexually active women up to 25 y/oAll women > 25 y/o with risk factorsMen with risk factorsComplications: (CDC)up to 30% of women with untreated PID. Left untreated, 20% of those with symptomatic PID might become infertile; 18% will experience debilitating, chronic pelvic pain; and 9% will have a life-threatening tubal pregnancy (8). The importance of subclinical PID became apparent with observations that most of the women with tubal factor infertility or ectopic pregnancy who had serologic evidence of chlamydial infection apparently had no history of PID (9,10). C. trachomatis infection during pregnancy might lead to infant conjunctivitis and pneumonia and maternal postpartum endometritis (11). Among men, urethritis is the most common illness resulting from C. trachomatis infection. Complications (e.g., epididymitis) affect a minority of infected men and rarely result in reproductive health sequelae (12).C. trachomatis infections of the rectum can result from unprotected anal intercourse and are typically asymptomatic but might progress to proctocolitis (13,14). Ocular infections can result in conjunctivitis in neonates and adults (15). Sexually acquired reactive arthritis also has been reported as a possible consequence of C. trachomatis infection (16).The CDC recommends that selected populations of high-risk men be screened because of high rates of chlamydial infection, if resources exist and if screening men would not materially impact screening in women.-men attending STD clinics; men participating in National Job Training programs; men <30 years of age in the military; men <30 years of age entering jail or juvenile detention; and men whose partners are diagnosed with chlamydia.The CDC also recommends retesting men treated for chlamydia within three months  because of the high risk of reinfection.The CDC also recommends that sexually active men who have sex with men (MSM) be screened at least annually.
9Cervicitis Symptoms Signs Diagnosis Abnormal vaginal discharge Intermenstrual vaginal bleedingSignsMucopurulent endocervical exudateSustained endocervical bleeding easily induced by cotton swabLeukorrhea (>10 WBC per HPF) is specific, but not sensitiveDiagnosisMicroscopyNAATCultureThe incubation period of symptomatic chlamydia generally ranges from 7 to 14 days following infection. However, it is unclear how long those with asymptomatic disease may carry the infection. In a systematic review of ten studies of untreated, uncomplicated genital chlamydial infections, detection of chlamydia persisted over the short term (weeks to months after diagnosis) in 56 to 89 percent
10Cervicitis GC and Chlamydia most common organisms isolated NAAT is preferred diagnostic testSaline prep to assess for PID, BV, TrichIn majority of cases no organism isolatedPresumptive treatment (azithromycin 1g PO) should be provided for women at increased risk for STIs (≤25 y/o, new or multiple sex partners, and those who engage in unprotected sex)
11ChlamydiaChlamydial genital infection is the most frequently reported infectious disease in the USIntracellular bacteriumMay be asymptomatic, or sx may occur weeks to months after exposure
12Screening Recommendations ChlamydiaScreening RecommendationsAnnually for all sexually active women ≤ 25 y/oAnnually for women > 25 w/ risk factorsScreen + patients for other STDs
13Chlamydia Treatment Recommended regimens (97-98% cure rate): Azithromycin 1 g PO single dose orDoxycyline 100 mg PO bid for 7dAlternative regimens:Erythromycin base 500 mg PO qid for 7dErythromycin ethylsuccinate 800 mg PO qid for 7dOfloxacin 300 mg PO bid for 7dLevofloxacin 500 mg PO qd for 7d
14Chlamydia Treatment Patient counseling Take first dose immediately (observed, on site, if possible)TOC is not advised routinely (except in pregnancy)Retest in 3 months to screen for re-infectionAdvise most recent partner and any other sex partners w/i 60 days preceding symptoms to seek evaluation/txAbstain from IC until pt and partner(s) complete tx (7d after single dose regimen)
15GonorrheaN. gonorrhoeae infections are the 2nd most common reportable communicable disease in the USTend to cause a stronger inflammatory response than C. trachomatis but are typically asymptomatic in women until complications such as PID developIn men, usually causes urethritis with painful urination. May cause epididymitis or disseminated gonococcal infection
16Gonorrhea Screening based on population, at risk pts Patients w/ + GC should be tested for chlamydia, syphilis, and HIVCulture and sensitivities for persistent infectionTx: cephalosprin + azithomycinNo TOC needed, but consider retesting after 3 months to screen for reinfectionRefer partners for testing/tx (most recent partner and all partners w/i 60d before onset of symptoms or + test)
17Vaginitis Vaginal discharge, odor, vulvar itching and irritation Most common causes arebacterial vaginosis (40%- 45%)vulvovaginal candidiasis (20%-25%)trichomoniasis (15%- 20%)
18Bacterial Vaginosis (BV) Polymicrobial clinical syndrome resulting from replacement of normal hydrogen peroxide-producing Lactobacillus species with anaerobic bacteriaPrevotella, Mobiluncus, G. Vaginalis, M. HominisMalodorous vaginal discharge reported more commonly after intercourse and after menses; +/- pruritusSx may remit spontaneouslyCan be diagnosed by clinical criteria or gram stain(BV) is a common condition that is related to alterations in the normal vaginal flora. It is the most common cause of vaginitis and has a recurrence rate of approximately 20%-40% at one month after therapy.Information on the prevalence of BV is incomplete since BV is not reportable. National data show that the prevalence is 29% but varies by population: 5%-25% in college students, 12%-61% in STD patients.Organisms associated with BV do not persist in the male urethra, but may be present under the foreskin of uncircumcised men. BV has been identified in female same-sex partnerships.BV has been linked to premature rupture of membranes, premature delivery, low-birthweight delivery, acquisition of HIV and STDs, development of pelvic inflammatory disease (PID), post-operation infections after gynecological procedures and recurrence of BV. Occurrence of BV may be related to sexual activity, but BV is not considered a sexually transmitted disease.Certain species of lactobacillus also produces hydrogen peroxide (H2O2), which is in vitro, toxic to viruses such as HIV as well as to bacteria. These species are present in approximately 42%-74% of females, and is under investigation as a probiotic. The prevalence of BV in these women is low (4%).Amsel criteria. The presence of three of the following four criteria provides sufficient evidence for a clinical diagnosis of BV.1. Vaginal pH >4.5, which is most sensitive but least specific sign.2. The presence of clue cells (bacterial clumping upon the borders of epithelial cells) on wet mount examination. Clue cells should constitute at least 20% of all epithelial cells (an occasional clue cell does not fulfill this criteria).3. Positive amine, "whiff" or "fishy odor" test (liberation of biologic amines with or without the addition of 10% KOH).4. Homogeneous, nonviscous, milky-white discharge adherent to the vaginal walls.Gold standard for diagnosis of BV is vaginal Gram stain to assist in the diagnosis of BV (Nugent criteria).
19BV Recommended Rx: Alternative Rx: Metronidazole 500 mg PO bid for 7dMetrogel 0.75% 5 g vaginally qd for 5dClindamycin cream 2% 5 g vaginally qd for 7dDo not use in second half of pregnancyAlternative Rx:Clindamycin 300 mg PO bid for 7dClindamycin ovules 100mg vaginally qhs x3dTinidazole 2 g po qd x2dTinidazole 1 g po qd x5dFor multiple recurrences, consider Metrogel 0.75% twice weekly for 6 monthsTreatment of male sex partners has not been beneficial in preventing recurrencePregnancy - Treat all symptomatic pregnant patients
20Trichomoniasis T. Vaginalis (a protozoan) 3% of US women currently infected70%-85% asymptomaticSx include "frothy" gray or yellow-green vaginal discharge and itchingAlmost always sexually transmittedWithout treatment, trichomoniasis can increase a person’s chances of getting or spreading other STIsIn women, infection with T. vaginalis has been suggested to be associated with adverse pregnancy outcomes, including premature rupture of membranes and pre-term labor, pelvic inflammatory disease, and increased risk for HIV infection3% prevalence in the general female population.• 1.3% in non-Hispanic white women• 1.8% in Mexican American women• 13.3% in non-Hispanic black women• Prevalence increases with age among non-Hispanic black women.• 40%-60% prevalence in female prison inmates and commercial sex workers.• 18%-50% prevalence in females with vaginal complaints.• 70%-85% of women are asymptomatic.• Not routinely tested in men. A 17% prevalence rate was seen in males attending an STD clinic in one city."frothy" gray or yellow-green vaginal discharge and pruritis. Cervical petechiae ("strawberry cervix") is a classic presentation which occurs <2% of cases. T. vaginalis may also infect the Skene's glands and the urethra where it can be difficult to treat. T. vaginalis infection is often asymptomatic in women. Trichomoniasis has been associated with increased shedding of HIV in HIV- infected women.
21Trichomoniasis Screening recommended in women: Diagnosis Motile trichomonads on wet prepOnly 60-70% sensitiveVarious point of care tests 80+% sensitiveCan culture if negative wet prep and high suspicionScreening recommended in women:with new or multiple partnerswith a history of STIswho trade sex for drugs or moneywho use IV drugsNucleic acid amplification tests (NAAT): Recently, the Trichomonas APTIMA test (GenProbe) was approved by the U.S. FDA for the diagnosis of vaginal trichomoniasis. This test is highly sensitive and specific and can be performed on self-collected or clinician-collected vaginal swab, urine or liquid endocervical cytology media. This test is considerably more sensitive than culture.
22Trichomoniasis Recommended treatment options Counseling Metronidazole 2 g PO x1 (or 500 mg BID x 7d)Tinidazole 2 g PO x1CounselingAbstain from alcohol until 24h after last metronidazole (3d for tinidazole)Advise partners to seek eval and txAvoid intercourse until all tx completed and both partners are asymptomaticBreastfeeding: withhold feeding for 12-24h after last dose of metronidazole (3d for tinidazole)Latex condoms, when used consistently and correctly, can reduce the risk of transmission of T. vaginalis.
23Vulvovaginal Candidiasis (VVC) “yeast infection”Caused by Candida albicans (85%- 90%), C. glabrata and C. parapsilosis are responsible for ~10% of casesSymptoms: vulvar itching; thick, white, clumpy Vaginal dischargeDiagnosis: wet prep, gram stain, or cultureMost cases of VVC are caused by Candida albicans (85%-90%). C. glabrata and C. parapsilosis are responsible for 5%-10% of cases.Although most patients have no risk factors, frequent infections may be linked to diabetes, corticosteroids, repeated courses of antibiotics, pregnancy, or HIV disease.Candida species are normal flora of the skin and the vagina and are not considered to be sexually transmitted pathogens. Yeast grows as oval budding cells and as chains of cells (pseudohyphae). Candida species may be isolated from the lower genital tract in approximately 20% of asymptomatic healthy women without abnormal discharge.Symptomatic candidiasis is caused by an overgrowth of Candida albicans and Candida species. It is thought that changes in the host vaginal environment are usually necessary before the organism induces pathologic effects.Disruption of normal vaginal ecology and host immunity can occur with diabetes, pregnancy, or HIV disease. In some women, disruption can occur with the use of antibiotics and douching.vulvar pruritus. Vaginal discharge is usually thick, white, and clumpy ("cottage-cheese-like"). However, it may be watery, minimal, or not present. Vaginal soreness, irritation, vulvar burning, dsypareunia, and external dysuria are often present.Cultures are not useful for routine diagnosis of VVC since positive cultures may detect colonization rather than clinically significant infections. However, cultures may be useful to detect non-albicans species or resistant organisms in women with recurrent disease.
24Treatment of uncomplicated VVC Multiple topical azoles, applied 1-7dOTC: butaconazole, clotrimazole, miconazole, tioconazoleRx: butoconazole, nystatin, terconazolenb: If symptoms persist after using OTC preparation or recur w/i 2 months should be evaluated with office- based testingOral agent (Rx): Fluconazole 150 mg x1Treat partners only if symptomatic (balanitis)Recurrent VVC≥4 episodes per yrObtain vaginal culturesTx: longer topical regimen (7-10d) or fluconazole PO x3 three days apartMaintenance - Oral fluconazole 150 mg Qwk for 6 monthsSevere VVCExtensive erythema, edema, excoriation, fissuresTx: opical azole for 7-14d or fluconazole 150 mg PO x2 three days apartNon-albicans VVC7-14d of topical azoleFor recurrence, boric acid 600 mg in gelatin capsule vaginally QD for 2 weeksImmunocompromisedPregnancyTopical azole x7 days
25Complicated VVC Recurrent VVC Severe VVC Recurrent Severe Non-albicans candidiasisWomen with uncontrolled diabetes, debilitation, or immunosuppressionRecurrent VVC≥4 episodes per yrObtain vaginal culturesTx: longer topical regimen (7-10d) or fluconazole PO x3 three days apartMaintenance - Oral fluconazole 150 mg Qwk for 6 monthsSevere VVCExtensive erythema, edema, excoriation, fissuresTx: opical azole for 7-14d or fluconazole 150 mg PO x2 three days apartNon-albicans VVC7-14d of topical azoleFor recurrence, boric acid 600 mg in gelatin capsule vaginally QD for 2 weeksImmunocompromisedPregnancyTopical azole x7 days
26PID Minimum diagnostic criteria Treat empirically Women at risk for STDs experiencing pelvic or lower abdominal pain, if no cause for the illness can be identified, and one or more of the following are present on pelvic examination:CMTUterine tendernessAdnexal tendernessTreat empiricallyScreen all PID pts for N. gonorrhoeae, C. trachomatis, HIV
27PID Recommended Parenteral Treatment: Regimen A Regimen B Cefotetan 2 g IV q12h OR Cefoxitin 2 g IV q6hPLUS Doxycycline 100 mg PO or IV q12hRegimen BClindamycin 900 mg IV q8hPLUS Gentamycin 2 mg/kg IV/IM load, then 1.5 mg/kg q8h (Can substitute single daily dosing)Alternative Parenteral Regimen:Ampicillin/Sulbactam 3 g IV q6h PLUS Doxy 100 mg IV or PO q12h
28PIDMay discontinue parenteral therapy 24 hrs after a clinical improvementContinue doxycycline 100 mg PO bid OR clindamycin 450 mg PO qid to complete total of 14d of RX (Clindamycin preferred with TOA)
29PID Recommended Oral Regimen Starts with single IM injection of Ceftriaxone 250 mgOr Cefoxitin 2g PLUS Probenicid 1g PO x1Or other 3rd gen cephalosporin (ceftizoxime, cefotaxime)PLUS 14 d PODoxycycline 100 mg bid+/- Metronidazole 500 mg PO bid
30PIDParental and oral therapy have similar efficacy in mild/moderate casesSuggested criteria for hospitalization:Cannot exclude appendicitis or other surgical emergencyPregnancyInadequate response to PO RxUnable to follow or tolerate PO RxSeverely ill, N/V, high fever, etc.TOA
31Genital UlcersIn the U.S. most likely to be genital herpes or syphilisOther possiblities:Chancroid, syphilisGranuloma InguinaleLymphogranuloma VenereumCDC: “All persons who seek evaluation and treatment for STDs should be screened for HIV infection. Screening should be routine, regardless of whether the patient is known or suspected to have specific behavioral risks for HIV infection.”Chancroid: Haemophilus ducreyiRare in US; endemic in AfricaDifficult to diagnoseGold standard = cultureSpecial culture media requiredSensitivity < 80%Presumptive dx by clinical criteriaPainful genital ulcer(s)Typical appearance of ulcers and inguinal lymphadenopathyNegative test for syphilis and HSVLG: Klebsiella granulomatisPainless progressive ulcerative lesions without regional lymphadenopathyLesions vascular and friable (beefy red)Dx requires visualization of dark-staining Donovan bodies on biopsy
32Genital HSVU.S. statistics >50 million persons in the U.S. have genital HSV infection >1 million new cases occur each year 17% of adults aged affected Transmission HSV-2 is transmitted sexually (genital to genital, oral to genital, or genital to oral) and perinatally (mother to child) HSV-1 transmission is usually non-sexual; but sexual transmission is increasingCDC: 50 million persons in the U.S. have genital HSV infection.It is estimated that at least 1 million new cases occur each year.In the general U.S. population, 17% of adults aged years have HSV-2 antibodies.HSV-2 antibodies are not routinely detected until puberty, and then HSV-2 seroprevalence increases with age. HSV-2 seroprevalence is higher in women than men in all age groups and varies by race/ethnicity.The majority of persons infected with HSV-2 have not been diagnosed with genital herpes (86% in the general U.S. population).TransmissionHSV-2 is transmitted sexually (genital to genital, oral to genital, or genital to oral) and perinatally (mother to child). HSV-1 is usually transmitted via a non-sexual route; however, sexual transmission appears to be increasing.The majority of genital herpes infections are transmitted by persons unaware that they have the infection or who are asymptomatic when transmission occurs.The risk of sexual transmission is difficult to quantify, but is estimated at >5% per year in
33Genital HSV Primary (initial) infection numerous bilateral painful lesionsmore severe, last longer, and have higher titers of virus than recurrent infections.papules vesicles pustules ulcers crusts healedsystemic symptomsPrimary (initial) infection without treatment: characterized by the occurrence of numerous bilateral painful genital lesions. These lesions are more severe, last longer, and have higher titers of virus than recurrent infections.Typical lesion progression: papules vesicles pustules ulcers crusts healed; though patients may present at any stage and lesions may be atypical (e.g., fissures).Often associated with systemic symptoms, including fever, headache, malaise, myalgia; may cause urinary retention in women.Illness lasts 2-4 weeks. Painful genital lesions that are numerous and bilateral last an average of days; full re-epithelialization takes an average of days.Systemic symptoms peak within 3-4 days of onset of lesions and gradually recede over the next 3-4 daysMedian duration of viral shedding detected by culture (from the onset of lesions to the last positive culture) is approximately 12 days, and correlates well with the mean time from the onset of vesicles to crusting.
34Genital HSV Recurrent infection Prodromal symptoms (localized tingling, irritation) hrs before lesionsRecurrent infection without treatmentProdromal symptoms (localized tingling, irritation) are common and begin hours before lesions and sometimes occur without lesions ("false prodrome").Duration of episodes is shorter than in primary infection: painful genital lesions last 4-6 days; average duration of viral shedding is 4 days.Lesions tend to be unilateral and much less extensive than with primary infection.Symptoms tend to be milder and less severe. Usually there are no systemic symptoms.Atypical presentations can occur, such as small linear ulcerations.Rate of cervical virus shedding during recurrences is 15-20%.Up to 90% of patients with symptomatic first episode HSV-2 infection will have a recurrence in the first 12 months of infection.
35Genital HSV Culture is confirmatory test Type-specific serologic tests Low sensitivity, esp. in recurrent lesionsPCR more sensitive, not FDA-clearedType-specific serologic testsSensitivity 80-98%, Specificity ≥ 96%Routine screening not indicatedUseful in the following scenarios:Recurrent genital symptoms or atypical symptoms with negative HSV culturesClinical diagnosis of genital herpes without laboratory confirmationPartner with genital herpesConsider for persons requesting STD evaluation, and for HIV+ ptsCDC: Clinical diagnosis is insensitive and nonspecific; therefore, the clinical diagnosis of genital herpes should be confirmed by laboratory testing..The typical painful multiple vesicular or ulcerative lesions are absent in many infected persons. Up to 50% of symptomatic first-episode cases are caused by HSV-1 in some populations, but recurrences and subclinical shedding are much less frequent for genital HSV-1 infection than genital HSV-2 infection, therefore HSV serotype influences prognosis and counseling.There are 2 main types of lab tests used for confirmatory diagnosis:Virologic testsType-specific serologic testsBoth virologic and type-specific serologic tests for HSV should be available in clinical settings that provide care for patients with STDs or those at risk for STDs.
36Genital HSV Treatment of initial episode Systemic antivirals for 7-10 daysAcyclovir, Famciclovir or ValacyclovirUse of topical antivirals discouragedRecurrent InfectionStart tx within 1 day of lesion onset or during prodromeSuppressive TherapyReduces frequency by 70-80%Decreases transmissionWhile serologic assays from HSV-2 should be available for persons who request them, screening for HSV-1 or HSV-2 infection in the general population is not indicated.Acyclovir 400 mg PO TID, or 200 mg PO 5x/dFamciclovir 250 mg PO TIDValacyclovir 1g PO BIDSuppressive TherapyQDValacyclovir 500 mgValacyclovir 1000 mgBIDAcyclovir 400 mgFamcyclovir 250 mg
37Genital HSV Patient counseling Potential for recurrent episodes, asymptomatic viral shedding, risks of sexual transmissionInform current and future partnersAbstain from sexual activity with uninfected partners when lesions or prodromal symptoms presentType-specific serologic testing recommended for asymptomatic partnersHSV-2 seropositive persons are at increased risk for HIV acquisition if exposed to HIVSuppressive antiviral therapy does not reduce this risk
38Genital HSVPregnancyWomen w/o genital herpes should abstain from intercourse during 3rd trimester w/ partners having known or suspected genital HSVSerologic testing is recommended for these womenDaily suppression for patients w/ genital HSV begining at 36 weeks (ACOG recommendations)Acyclovir 400 mg PO TID (more data in pregnancy) orValacyclovir 500 mg PO BIDC-section for women with active lesions at onset of labor
40Syphilis – DiagnosisDefinative dx requires darkfield exam of lesion exudate or tissueSerologic tests can be used to make presumptive DxNontreponemal – VDRL, RPRCorrelate with disease activity; should be reported quantitativelyLow levels may persistTreponema pallidumTreponemal – FTA-ABS, TP-PA, EAIsTest will remain + in > 75% of pts treated for primary syphilisMust be + on both types of serologic tests to make dx
41Syphilis - Rx Penicillin G Primary, Secondary, Early Latent: Benzathine penicillin G 2.4 million units IM X1Late latent, treatment failures, tertiary not neurosyphilis: Benzathine penicillin G 2.4 million units IM weekly X3NeurosyphilisAqueous crystalline PCN G million units per day for daysAlternative: Procaine PCN 2.4 million units IM qd PLUS Probenecid 500mg po qid for days
42Syphilis - Rx Special considerations Partners exposed w/i 90 days of primary/secondary/ early latent syphilis should be treated presumptivelyPregnant patients allergic to PCN should be skin tested and desensitized and treated w/ PCN
43Human Papillomavirus (HPV) > 100 types> 40 can infect the genital areaOncogenic, or high-risk types (e.g.16,18), cause cervical cancerNononcogenic, or low-risk types (e.g. 6,11), cause genital warts and recurrent respiratory papillomatosis14.1 million infections/year in the U.S.> 50% of sexually active persons are infected at least onceDx is usually clinical; can be confirmed by bxGenital wartsIncidence may be as high as 100/100,000.An estimated 1.4 million may be affected at any one time.Cervical cancerRates of cervical cancer have fallen by approximately 75% since the introduction of Pap screening programs.Incidence is estimated at 8.1/100,000.
44HPV Clinical manifestations of infection: Genital warts Cervical cellular abnormalities detected by Pap testsSome anogenital squamous cell cancersSome oropharyngeal cancersRecurrent respiratory papillomatosisMost infections are transient, asymptomatic or subclinical, and have no clinical consequences in immunocompetent individuals.Time to development of clinical manifestations is unclear, but most likely3 weeks to months for genital warts,Several months to years for cervical cellular abnormalities, andDecades for cervical cancers.The median duration of new cervical infections (measured by detection of HPV DNA) is 8 months, but varies.70% of new infections clear within 1 year.90% of new infections clear within 2 years.The gradual development of an effective immune response is thought to be the likely mechanism for HPV DNA clearance.
45HPV Prevention Two HPV vaccines are licensed in the US: Cervarix® – types 16, 18Gardasil® – types 6, 11, 16, 18Indicated in 9 – 26 y/oCDC recommends first dose at age yearsOnly Gardasil® has male indicationCondoms may reduce risk but not fully protectiveTypes 16 and 18 cause 70% of cervical cancers. types 6 and 11 cause 90% of genital warts.The Advisory Committee on Immunization Practices (ACIP) recommends that if the vaccination series is interrupted for any length of time, it can be resumed without restarting the series.HPV vaccination is not currently recommended for women over age 26 years. Clinical trials showed that, overall, HPV vaccination offered women limited or no protection against HPV-related diseases. For women over age 26 years, the best way to prevent cervical cancer is to get routine cervical cancer screening, as recommended.
46HPVTreatmentGoal is alleviation of symptoms; tx does not lower risk of transmission or development of malignancyTreatment method is guided by preference of the patient, available resources, and experience of the providerIn general, warts located on moist surfaces or in intertriginous areas respond best to topical treatmentMost genital warts respond within 3 months of therapyRecurrence common after tx, especially in first 3 mosTypes 16 and 18 cause 70% of cervical cancers. types 6 and 11 cause 90% of genital warts.The Advisory Committee on Immunization Practices (ACIP) recommends that if the vaccination series is interrupted for any length of time, it can be resumed without restarting the series.HPV vaccination is not currently recommended for women over age 26 years. Clinical trials showed that, overall, HPV vaccination offered women limited or no protection against HPV-related diseases. For women over age 26 years, the best way to prevent cervical cancer is to get routine cervical cancer screening, as recommended.
47HPV Patient-applied Wash w/ soap & water 6-10 hrs after application Podofilox 0.5% solution/gel applied w/ cotton swab bid x 3d followed by 4d of no tx; repeat up to 4 cyclesImiquimod 5% cream QHS 3x per week for up to 16 weeks.Wash w/ soap & water 6-10 hrs after applicationSinecatechins 15% ointmentSafety in pregnancy not established (all 3)Provider-appliedCryotherapy every 1-2 weeksPodophyllin resin 10-25% in a compound tincture of benzoinTCA (or BCA) 80-90% solution weeklySurgical removal (sharp, currette, or laser)Intralesional interferonAvailable therapies for genital warts likely reduce, but probably do not eradicate, HPV infectivity. Whether the reduction in HPV viral DNA resulting from treatment reduces future transmission remains unclearNo definitive evidence suggests that any of the available treatments are superior to any other, and no single treatment is ideal for all patients or all warts.Pdofilox: The total wart area treated should not exceed 10 cm2, and the total volume of podofilox should be limited to 0.5 mL per day. If possible, the health-care provider should apply the initial treatment to demonstrate the proper application technique and identify which warts should be treated. Mild to moderate pain or local irritation might develop after treatment. The safety of podofilox during pregnancy has not been established.Imiquimod is a topically active immune enhancer that stimulates production of interferon and other cytokines.Sinecatechin ointment, a green-tea extract with an active product (catechins), should be applied three times daily (0.5-cm strand of ointment to each wart) using a finger to ensure coverage with a thin layer of ointment until complete clearance of warts. This product should not be continued for longer than 16 weeks (409–411). The medication should not be washed off after use. Sexual (i.e., genital, anal, or oral) contact should be avoided while the ointment is on the skin.Podophyllin resin 10%–25% should be applied to each wart and allowed to air-dry before the treated area comes into contact with clothingBoth TCA and BCA are caustic agents that destroy warts by chemical coagulation of proteins. Although these preparations are widely used, they have not been investigated thoroughly. TCA solutions have a low viscosity comparable with that of water and can spread rapidly if applied excessively; therefore, they can damage adjacent tissues. A small amount should be applied only to the warts and allowed to dry before the patient sits or stands, at which time a white frosting develops. If pain is intense, the acid can be neutralized with soap or sodium bicarbonate. If an excess amount of acid is applied, the treated area should be powdered with talc, sodium bicarbonate (i.e., baking soda), or liquid soap preparations to remove unreacted acidSurgical therapy has the advantage of usually eliminating warts at a single visit. However, such therapy requires substantial clinical training, additional equipment, and a longer office visit. After local anesthesia is applied, the visible genital warts can be physically destroyed by electrocautery, in which case no additional hemostasis is required. Care must be taken to control the depth of electrocautery to prevent scarring. Alternatively, the warts can be removed either by tangential excision with a pair of fine scissors or a scalpel, by laser, or by curettage. Because most warts are exophytic, this procedure can be accomplished with a resulting wound that only extends into the upper dermis. Hemostasis can be achieved with an electrocautery unit or a chemical styptic (e.g., an aluminum chloride solution). Suturing is neither required nor indicated in most cases if surgical removal is performed properly. Surgical therapy is most beneficial for patients who have a large number or area of genital warts. Both carbon dioxide laser and surgery might be useful in the management of extensive warts or intraurethral warts, particularly for those persons who have not responded to other treatments.
48HPV Recommended Regimens for Vaginal or Anal Warts Cryotherapy with liquid nitrogenorTCAAvoid Imiquimod, sinecatechins, podophyllin, and podofilox in pregnancyRarely, HPV types 6 and 11 can cause respiratory papillomatosis in infants and children, although the route of transmission (i.e., transplacental, perinatal, or postnatal) is not completely understood. Whether cesarean section prevents respiratory papillomatosis in infants and children also is unclear; therefore, cesarean delivery should not be performed solely to prevent transmission of HPV infection to the newborn. Cesarean delivery is indicated for women with genital warts if the pelvic outlet is obstructed or if vaginal delivery would result in excessive bleeding.
49Hepatitis B Half symptomatic Sx include jaundice, fatigue, mild fever, nausea, vomiting, abdominal pain, and dark urine1% acute liver failure2-6% result in chronic hepatitis (up to 25% mortality)Transmissionpercutaneous or mucous membrane exposure to body fluids that contain bloodVertical (birth), horizontal (premastication)risk factors: unprotected sex, multiple partners, MSM, history of other STDs, illegal injection-drug use
50Hepatitis B No specific therapy for acute hepatitis B Focus is on preventionhepatitis B immune globulin (HBIG)provides temporary (3–6 mo) protection from HBV infectionhepatitis B vaccine
51Hepatitis B CDC national strategy to eliminate HBV transmission Prevention of perinatal infectionroutine screening of all pregnant women for HBsAgimmunoprophylaxis of infants born to HBsAg + mothers or mothers with unknown statusRoutine infant vaccinationVaccination of unvaccinated children through 18 y/oVaccination of previously unvaccinated adults at increased risk for infection
52Hepatitis C Most common chronic blood-born infection in US May be asx of have mild sxChronic HCV infection develops in 70%–85% of HCV-infected persons; 60%–70% of chronically infected persons develop evidence of active liver disease.Transmissionparenteral exposure to contaminated bloodnot efficiently transmitted sexuallyverticalScreening for Hep C:Anyone in the United States born between 1945 and 1965Those with a history of illicit injection drug use or intranasal cocaine use, even if only used onceThose who received clotting factors made before 1987Those who received blood/organs before July 1992Those who have been informed that they received blood from a donor who later tested positive for HCVThose who were ever on chronic hemodialysisThose with evidence of liver disease (persistently elevated alanine aminotransferase [ALT] level)Those infected with HIVChildren born to HCV-infected mothersThose with a needle stick injury or mucosal exposure to HCV-positive bloodThose who are a current sexual partner of an HCV-infected personIncarcerated individuals
53Hepatitis C Prevention No vaccine No immune globulin prophylaxis Condomsadvise for anyone with more than one partnerespecially important for HIV-infected menmay not be necessary in monogomous heterosexual partner-pairsRoutine testing in pregnancy is not recommendedTreatmentSpecialist referral - pegylated interferon and ribavirin
54Pediculosis Pubis (Pubic Lice) Usually transmitted by sexual contactRecommended RegimensPermethrin 1% cream rinsewash off after 10 minPyrethrins w/ peperonyl butoxidewash off after 10 minutesAlternative RegimensMalathion 0.5% lotion apply for 8-12 hrs then wash offIvermectin 250 mcg/kg repeat in 2 weeksWash and heat dry bedding, linenEvaluate for other STDsPartners should be treatedPermethrin ok for pregnant patients
55Scabies Usually sexually acquired in adults (not so in children) Recommended RXPermethrin cream 5% applied to all areas of body from neck down & washed off after 8-14hIvermectin 200 mcg/kg PO, repeat in 2 wksAlternative RXLindane 1% 1oz of lotion or 30 g cream applied to all areas from neck down & washed off after 8hWash & dry bedding, clothingRash may persist for up to 2 weeks after RxExamine and treat sexual/household contactsLindane is not recommended as first-line therapy because of toxicity; should not be used immediately after a bath or shower, and it should not be used by persons who have extensive dermatitis, women who are pregnant or lactating, or children aged <2 years.Permethrin for pregnant patients
56Screening in Sexual Assault GC and Chlamydia (NAAT); collect specimens from any site of attempted penetrationWet mount and culture of vaginal swab for TrichmonadsIf + vaginal discharge examine for BV and candida alsoSerum for HIV, Hep B, and syphilis (RPR/VDRL)Treat impiracally for Chlamydia, GC, Trich, BV; give Hep B vaccine for susceptible ptsFollow up…Repeat exam for STIs in 1-2 weeks if prophylactic Rx was not given or if patient has symptomsRepeat HIV and RPR/VDRL at 6 wks, 3 mo, and 6 moF/U Hep B vaccine 1-2 and 4-6 monthsProphylactic therapyEmergency contraception in at-risk patientsEmpiric tx for Chlamydia, GC, Trich, BV:Ceftriaxone 250 mg IM x1 or cefixime 400mg po x1Metronidazole 2 g PO x1Azithro 1g PO x1 or Doxycyline 100 mg PO bid x7dHIV prophylaxis of unproven benefit but should be discussed
57Screening in Pregnancy Ask all about STD hx, symptoms, and risk factorsScreening tests for all pregnant pts:HIV early in pregnancy* (opt-out screening)Syphilis at the first prenatal visit*Hepatitis B (HBsAg) early in pregnancyeven if they have been previously vaccinated or testedRetest at the time of admission for delivery if + high risk behaviors or clinical hepatitis*Pregnant women at risk for HBV infection also should be vaccinatedChlamydia trachomatis during the 1st prenatal visitRetest in 3rd trimester if ≤25 y/o, increased risk for chlamydia, and those with + 1st trimester screeningHigh risk behaviors for HBV = having had more than one sex partner in the previous 6 months, evaluation or treatment for an STD, recent or current injection-drug use, and an HBsAg-positive sex partner.Increased risk for chlamydia = women who have a new or more than one sex partnerRapid HIV test in labor if undocumented HIV statusEvidence does not support routine testing for bacterial vaginosis (BV), Trichomonas vaginalis , or HSV-2 in pregnancy.* Some states (including TX) require repeat screening in 3rd trimester or at delivery
58Screening in Pregnancy Consider screening for:Neisseria gonorrhoeae for women at risk for gonorrhea or living in an area where prevalence is highTest at first prenatal visitRetest in 3rd trimester if + in 1st trimester or pt at high riskHepatitis C at the first prenatal visit if high riskHigh risk behaviors for HBV = having had more than one sex partner in the previous 6 months, evaluation or treatment for an STD, recent or current injection-drug use, and an HBsAg-positive sex partner.Increased risk for chlamydia = women who have a new or more than one sex partnerRapid HIV test in labor if undocumented HIV statusHigh risk for gonorrhea: aged <25 years, previous gonorrhea infection, other STDs, new or multiple sex partners, inconsistent condom use, commercial sex work, and drug use.High risk for hepatitis C infection = those with a history of injection-drug use and those with a history of blood transfusion or organ transplantion before 1992Evidence does not support routine testing for bacterial vaginosis (BV), Trichomonas vaginalis , or HSV-2 in pregnancy.